2610035D17Rikem1Zhgn/2610035D17Rikem1Zhgn
Krasem1Gpt/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: C57BL/6JGpt * CBA
|
decreased gland tumor incidence |
J:339253
|
2610035D17Rikem2Zhgn/2610035D17Rikem2Zhgn
Krasem1Gpt/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53em3Gpt/Trp53+
involves: C57BL/6JGpt * CBA
|
decreased gland tumor incidence |
J:339253
|
Albtm1(cre/ERT2)Mtz/Alb+
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased hepatocellular carcinoma incidence |
J:254370
|
Apctm2.1Cip/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129P2/OlaHsd * 129S4/SvJae * FVB
|
increased intestinal adenocarcinoma incidence |
J:132357
|
|
premature death |
J:132357
|
Apctm2Rak/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL
|
increased colon adenoma incidence |
J:276349
|
|
premature death |
J:276349
|
Apctm2Rak/Apc+
Krastm1.1Khai/Kras+
Tg(Fabp1-cre)1Jig/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
increased colon adenoma incidence |
J:276349
|
|
premature death |
J:276349
|
Apctm2Rak/Apctm2Rak
Krastm4Tyj/Kras+
involves: 129 * 129S4/SvJae * C57BL/6J * SJL
|
increased adenocarcinoma incidence |
J:156532
|
|
increased carcinoma incidence |
J:156532
|
|
increased colon adenoma incidence |
J:156532
|
|
increased organ/body region tumor incidence |
J:156532
|
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Krastm4Tyj/Kras+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
increased adenocarcinoma incidence |
J:125101
|
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
hyperpigmentation |
J:161180
|
|
increased tumor incidence |
J:161180
|
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
involves: 129S1/Sv * 129X1/SvJ
|
increased lung non-small cell carcinoma incidence |
J:172200
|
|
premature death |
J:172200
|
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
decreased cell proliferation |
J:172200
|
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased cell proliferation |
J:172200
|
Braftm2Cpri/Braf+
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
increased fibroblast proliferation |
J:187371
|
|
increased lung adenoma incidence |
J:187371
|
Brca1tm1Thl/Brca1tm1Thl
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm1Thl/Brca1tm2Rjbr
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm1Thl/Brca1tm3.1Rjbr
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca2tm1Brn/Brca2tm1Cam
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic acinar cell carcinoma incidence |
J:166678
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brca2tm1Cam/Brca2tm1Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
exocrine pancreatic insufficiency |
J:166678
|
|
increased pancreas apoptosis |
J:166678
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brf1tm1Arte/Brf1tm1Arte
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:285667
|
|
premature death |
J:285667
|
Ccne1tm1Jro/?
Krastm3Tyj/?
either: (involves: 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6)
|
chromosome breakage |
J:99695
|
|
premature death |
J:99695
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6N * FVB/N
|
decreased glutamic acid level |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
decreased tumor growth/size |
J:280854
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
premature death |
J:280854
|
Cdk2tm1Sgo/Cdk2tm1Sgo
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
decreased tumor incidence |
J:161780
|
|
premature death |
J:161780
|
Cdk2tm2Sgo/Cdk2tm2Sgo
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
decreased tumor incidence |
J:161780
|
|
premature death |
J:161780
|
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6
|
abnormal pancreatic duct morphology |
J:86101
|
|
increased hemangiosarcoma incidence |
J:86101
|
|
increased lung adenoma incidence |
J:86101
|
|
increased papilloma incidence |
J:86101
|
|
increased pituitary adenoma incidence |
J:86101
|
|
increased sarcoma incidence |
J:86101
|
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
decreased cell proliferation |
J:161780
|
|
decreased tumor growth/size |
J:161780
|
|
early cellular replicative senescence |
J:161780
|
|
increased adenocarcinoma incidence |
J:161780
|
Cdk4tm2.2Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
decreased cell proliferation |
J:161780
|
|
decreased tumor growth/size |
J:161780
|
|
decreased tumor incidence |
J:161780
|
|
early cellular replicative senescence |
J:161780
|
|
increased tumor incidence |
J:161780
|
Cdk4tm2.2Bbd/Cdk4tm2.2Bbd
Krastm1Bbd/Krastm1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
decreased tumor incidence |
J:161780
|
Cdk6tm1Bbd/Cdk6tm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ
|
increased adenoma incidence |
J:161780
|
|
increased lung non-small cell carcinoma incidence |
J:161780
|
|
premature death |
J:161780
|
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N
|
ascites |
J:198619
|
|
distended abdomen |
J:198619
|
|
increased adenocarcinoma incidence |
J:198619
|
|
increased pancreas adenoma incidence |
J:198619
|
|
increased pancreas tumor incidence |
J:198619
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:198619
|
|
jaundice |
J:198619
|
|
premature death |
J:198619
|
|
weight loss |
J:198619
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Krastm4Tyj/Kras+
involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL
|
increased lung adenocarcinoma incidence |
J:124682
|
|
premature death |
J:124682
|
Cdkn2atm2.1Nesh/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
|
increased tumor growth/size |
J:164588
|
|
premature death |
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2atm2.1Nesh Krastm4Tyj
|
hyperpigmentation |
J:220627
|
|
increased cutaneous melanoma incidence |
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129S4/SvJae * C57BL/6 * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:124682
|
|
increased metastatic potential |
J:124682
|
|
premature death |
J:124682
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
|
ascites |
J:198619
|
|
distended abdomen |
J:198619
|
|
increased adenocarcinoma incidence |
J:198619
|
|
increased pancreas adenoma incidence |
J:198619
|
|
increased pancreas tumor incidence |
J:198619
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:198619
|
|
jaundice |
J:198619
|
|
premature death |
J:198619
|
|
weight loss |
J:198619
|
Cdkn2atm2Brn/Cdkn2atm2Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S4/SvJae * FVB/N
|
abnormal pancreas development |
J:195229
|
|
increased cell proliferation |
J:195229
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129 * FVB/N
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
|
increased tumor incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
|
increased stomach tumor incidence |
J:116130
|
|
increased tumor incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:195492
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
increased sarcoma incidence |
J:125101
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
increased pancreatic ductal adenocarcinoma incidence |
J:187012
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N
|
decreased tumor-free survival time |
J:87196,
J:116130
|
|
increased malignant tumor incidence |
J:87196
|
|
increased metastatic potential |
J:87196,
J:108298
|
|
increased pancreas tumor incidence |
J:87196,
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:87196,
J:108298,
J:116130
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:87196
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129 * FVB/N
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
|
increased stomach tumor incidence |
J:116130
|
|
increased tumor incidence |
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal metabolism |
J:151781
|
|
increased pancreas tumor incidence |
J:151781
|
|
pancreas cyst |
J:151781
|
Chaf1btm2c(EUCOMM)Hmgu/Chaf1b+
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6J * C57BL/6N * CBA/J
|
normal
hematopoietic system phenotype |
J:266848
|
|
increased leukocyte cell number |
J:266848
|
|
premature death |
J:266848
|
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
cachexia |
J:171191
|
|
increased lung adenoma incidence |
J:171191
|
|
increased tumor incidence |
J:171191
|
|
premature death |
J:171191
|
|
respiratory distress |
J:171191
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
increased granulosa cell tumor incidence |
J:186144
|
|
increased testis tumor incidence |
J:186144
|
|
seminiferous tubule degeneration |
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased lung tumor incidence |
J:174242
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm4Tyj/Kras+
Tg(CYP19A1-cre)1Jri/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
|
decreased circulating estradiol level |
J:186144
|
|
decreased circulating progesterone level |
J:186144
|
|
impaired granulosa cell differentiation |
J:186144
|
|
increased circulating follicle stimulating hormone level |
J:186144
|
|
increased circulating luteinizing hormone level |
J:186144
|
|
increased granulosa cell tumor incidence |
J:186144
|
|
increased ovary tumor incidence |
J:186144
|
|
premature death |
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
increased prostate gland tumor incidence |
J:143034
|
|
premature death |
J:143034
|
|
squamous metaplasia of bulbourethral gland |
J:143034
|
|
squamous metaplasia of urethral gland |
J:143034
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased urinary bladder carcinoma incidence |
J:234236
|
|
premature death |
J:234236
|
Deptortm1.2Ysun/Deptortm1.2Ysun
Krastm4Tyj/Kras+
Ube2cem1Gpt/Ube2cem1Gpt
involves: 129S4/SvJae * C57BL/6J
|
increased lung tumor incidence |
J:333347
|
Dhx33em1Yazh/Dhx33+
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
decreased lung tumor incidence |
J:299900
|
Dhx33em1Yazh/Dhx33em1Yazh
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
decreased lung tumor incidence |
J:299900
|
Diras2em1Gpt/Diras2em1Gpt
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae * C57BL/6J * C57BL/6JGpt
|
increased pancreatic ductal adenocarcinoma incidence |
J:348744
|
Diras2em1Gpt/Diras2em1Gpt
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
Ube2ftm1c(EUCOMM)Hmgu/Ube2ftm1c(EUCOMM)Hmgu
involves: 129S4/SvJae * C57BL/6
|
increased pancreas tumor incidence |
J:348744
|
Dmtf1tm1Cjs/Dmtf1+
Krastm2Tyj/Kras+
involves: 129S2/SvPas * C57BL/6
|
abnormal metastatic potential |
J:126002
|
|
decreased tumor latency |
J:126002
|
|
increased cholangiocarcinoma incidence |
J:126002
|
|
increased lung adenocarcinoma incidence |
J:126002
|
|
increased lung adenoma incidence |
J:126002
|
|
increased lung tumor incidence |
J:126002
|
|
increased neurofibroma incidence |
J:126002
|
|
increased osteosarcoma incidence |
J:126002
|
|
increased skin papilloma incidence |
J:126002
|
|
increased T cell derived lymphoma incidence |
J:126002
|
|
premature death |
J:126002
|
Dmtf1tm1Cjs/Dmtf1+
Krastm3Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
abnormal metastatic potential |
J:126002
|
|
decreased tumor latency |
J:126002
|
|
increased lung adenocarcinoma incidence |
J:126002
|
|
increased lung adenoma incidence |
J:126002
|
|
increased lung tumor incidence |
J:126002
|
|
increased skin papilloma incidence |
J:126002
|
|
increased T cell derived lymphoma incidence |
J:126002
|
|
premature death |
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm2Tyj/Kras+
involves: 129S2/SvPas * C57BL/6
|
abnormal metastatic potential |
J:126002
|
|
decreased tumor latency |
J:126002
|
|
increased lung adenocarcinoma incidence |
J:126002
|
|
increased lung adenoma incidence |
J:126002
|
|
increased lung tumor incidence |
J:126002
|
|
increased ovary tumor incidence |
J:126002
|
|
increased skin papilloma incidence |
J:126002
|
|
increased T cell derived lymphoma incidence |
J:126002
|
|
premature death |
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm3Tyj/Kras+
involves: 129S4/SvJae * C57BL/6
|
decreased tumor latency |
J:126002
|
|
increased lung adenocarcinoma incidence |
J:126002
|
|
increased lung adenoma incidence |
J:126002
|
|
increased lung tumor incidence |
J:126002
|
|
increased skin papilloma incidence |
J:126002
|
|
increased T cell derived lymphoma incidence |
J:126002
|
|
premature death |
J:126002
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Waptm1(cre)Arge/Wap+
involves: 129S1/Sv
|
decreased tumor-free survival time |
J:146290
|
|
increased mammary adenocarcinoma incidence |
J:146290
|
|
increased mammary gland tumor incidence |
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Tg(Hsp70-1-cre)1Arge/0
involves: 129S1/Sv * C57BL/6J * CBA
|
embryonic lethality |
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Igf1rtm2Arge/Igf1r+
Waptm1(cre)Arge/Wap+
involves: 129S1/Sv
|
decreased tumor-free survival time |
J:146290
|
|
increased mammary gland tumor incidence |
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+
Igf1rtm2Arge/Igf1rtm2Arge
Waptm1(cre)Arge/Wap+
involves: 129S1/Sv
|
decreased tumor-free survival time |
J:146290
|
|
increased mammary gland tumor incidence |
J:146290
|
Eif4eGt(RRO036)Byg/Eif4e+
Krastm3Tyj/Kras+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
decreased lung tumor incidence |
J:224214
|
|
decreased tumor growth/size |
J:224214
|
|
increased cellular sensitivity to oxidative stress |
J:224214
|
|
oxidative stress |
J:224214
|
Epha2tm1Jrui/Epha2tm1Jrui
Krastm4Tyj/Kras+
Trp53tm2.1Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S/SvEv * 129S4/SvJae * FVB/N
|
abnormal survival |
J:244261
|
|
decreased metastatic potential |
J:244261
|
|
normal
neoplasm |
J:244261
|
Fastm1Ach/Fastm1Ach
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae
|
decreased ovarian tumor incidence |
J:161953
|
Fbxw7tm1Iken/Fbxw7+
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA
|
bile duct hyperplasia |
J:258194
|
|
dilated bile duct |
J:258194
|
Fbxw7tm1Iken/Fbxw7tm1Iken
Krastm4Tyj/Kras+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA
|
increased cholangiocarcinoma incidence |
J:258194
|
Fgfr3tm4Cxd/Fgfr3+
Krastm4Tyj/Kras+
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
|
increased skin papilloma incidence |
J:174242
|
|
normal
neoplasm |
J:174242
|
|
premature death |
J:174242
|
Flt4tm1.1Ichi/Flt4+
Krastm1Mok/Kras+
involves: 129S/SvEv * C57BL/6
|
chylous ascites |
J:159024
|
|
lymphatic vessel hypoplasia |
J:159024
|
|
lymphedema |
J:159024
|
Flt4tm1.1Ichi/Flt4+
Krastm1Mok/Kras+
Tg(HRAS)2Jic/0
involves: 129S/SvEv * BALB/c * C57BL/6 * DBA/2
|
chylous ascites |
J:159024
|
|
lymphatic vessel hypoplasia |
J:159024
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
abnormal cell cycle |
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
decreased tumor growth/size |
J:158937
|
|
increased lung tumor incidence |
J:158937
|
|
increased lung weight |
J:158937
|
|
premature death |
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
abnormal lung epithelium morphology |
J:158937
|
|
decreased tumor growth/size |
J:158937
|
|
increased lung adenoma incidence |
J:158937
|
|
increased lung carcinoma incidence |
J:158937
|
|
increased lung tumor incidence |
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
decreased tumor growth/size |
J:158937
|
|
increased lung tumor incidence |
J:158937
|
|
premature death |
J:158937
|
Fntbtm1Bbd/Fntbtm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
increased lung adenocarcinoma incidence |
J:98944
|
|
increased lung adenoma incidence |
J:98944
|
Gfi1tm5.1(GFI1*)Tmo/Gfi1+
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA
|
myeloid hyperplasia |
J:192927
|
|
premature death |
J:192927
|
Gfi1tm5.1(GFI1*)Tmo/Gfi1tm5.1(GFI1*)Tmo
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA
|
myeloid hyperplasia |
J:192927
|
|
premature death |
J:192927
|
Gfi1tm6.1(GFI1)Tmo/Gfi1tm6.1(GFI1)Tmo
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA
|
myeloid hyperplasia |
J:192927
|
|
premature death |
J:192927
|
Ggctem1.2Smoc/Ggctem1.2Smoc
Krastm4Tyj/Kras+
involves: 129S4/SvJae * C57BL/6J
|
decreased fibroblast proliferation |
J:317466
|
|
decreased tumor incidence |
J:317466
|
Gt(ROSA)26Sortm1(CAG-Mir182)Dgk/Gt(ROSA)26Sortm1(CAG-Mir182)Dgk
Krastm4Tyj/Krastm4Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased metastatic potential |
J:217635
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA
|
increased susceptibility to induced pancreatitis |
J:289183
|
|
pancreatic acinar-to-ductal metaplasia |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi
involves: 129 * C57BL/6 * CBA
|
decreased gland tumor incidence |
J:289183
|
|
normal
endocrine/exocrine gland phenotype |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi
Trp53tm1Brn/Trp53+
involves: 129 * C57BL/6 * CBA
|
normal
endocrine/exocrine gland phenotype |
J:289183
|
|
normal
mortality/aging |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Brn/Trp53+
involves: 129 * C57BL/6 * CBA
|
increased pancreas tumor incidence |
J:289183
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:289183
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:289183
|
|
pancreatic acinar-to-ductal metaplasia |
J:289183
|
|
premature death |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:280854
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
|
premature death |
J:280854
|
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev
Krastm4Tyj/Krastm4Tyj
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased lung adenoma incidence |
J:142030
|
|
increased lung tumor incidence |
J:142030
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S4/SvJae * 129S4/SvJaeSor
|
increased pancreatic intraepithelial neoplasia incidence |
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * CBA
|
increased pancreatic intraepithelial neoplasia incidence |
J:142188
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:187582
|
|
increased tumor growth/size |
J:187582
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:186194
|
|
pancreatic acinar-to-ductal metaplasia |
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J
|
increased pancreatic ductal adenocarcinoma incidence |
J:140423
|
|
premature death |
J:140423
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Pms2tm2(cre)Lisk/Pms2tm2(cre)Lisk
involves: 129S4/SvJae * 129S4/SvJaeSor
|
abnormal mismatch repair |
J:204653
|
|
increased lung tumor incidence |
J:204653
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae * 129S6/SvEvTac
|
normal
endocrine/exocrine gland phenotype |
J:197054
|
|
normal
neoplasm |
J:197054
|
Gt(ROSA)26Sortm2(Rnf187)Jhai/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Vil1-cre)20Syr/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal enterocyte proliferation |
J:173145
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129 * C57BL/6NCrl * FVB/N
|
increased metastatic potential |
J:245611
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Prdm1tm1Clme/Prdm1tm1Clme
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129 * C57BL/6NCrl * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:245611
|
|
premature death |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Hmga2tm1.1Mmw/Hmga2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N
|
increased metastatic potential |
J:245611
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N
|
abnormal translation |
J:285667
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:285667
|
|
premature death |
J:285667
|
Hrastm1Mok/Hrastm1Mok
Krastm1Mok/Kras+
involves: 129S/SvEv * C57BL/6 * DBA/2
|
chylous ascites |
J:159024
|
Hrastm1Mok/Hrastm1Mok
Krastm1Mok/Kras+
Nrastm1Mok/Nras+
involves: 129S/SvEv * C57BL/6 * DBA/2
|
chylous ascites |
J:159024
|
Hrastm1Mok/Hrastm1Mok
Krastm1Mok/Kras+
Nrastm1Mok/Nras+
Tg(HRAS)2Jic/0
involves: 129S/SvEv * BALB/c * C57BL/6 * DBA/2
|
normal
homeostasis/metabolism phenotype |
J:159024
|
Hrastm1Mok/Hrastm1Mok
Krastm1Mok/Krastm1Mok
either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * DBA/2)
|
embryonic lethality during organogenesis, complete penetrance |
J:135610
|
Hrastm1Mok/Hrastm1Mok
Krastm1Mok/Krastm1Mok
Nrastm1Mok/Nrastm1Mok
Tg(HRAS)7Mok/0
either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * DBA/2)
|
no abnormal phenotype detected |
J:135610
|
Krastm1(Hras)Rdl/Krastm1(Hras)Rdl
either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
abnormal systemic arterial blood pressure |
J:98940
|
|
cardiac fibrosis |
J:98940
|
|
decreased heart left ventricle muscle contractility |
J:98940
|
|
dilated cardiomyopathy |
J:98940
|
|
hypertension |
J:98940
|
|
increased myocardial fiber size |
J:98940
|
|
increased systemic arterial diastolic blood pressure |
J:98940
|
|
increased systemic arterial systolic blood pressure |
J:98940
|
Krastm1.1Hbji/Krastm1.1Hbji
Trp53tm5Tyj/Trp53tm5Tyj
involves: 129S4/SvJae
|
increased fibroblast proliferation |
J:220921
|
|
increased lung adenoma incidence |
J:220921
|
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:276349
|
|
premature death |
J:276349
|
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N
|
increased metastatic potential |
J:119988
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:119988
|
|
premature death |
J:119988
|
Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
abnormal lung development |
J:122397
|
|
abnormal tumor incidence |
J:122397
|
|
enlarged lung |
J:122397
|
|
increased lung adenocarcinoma incidence |
J:122397
|
|
increased lung adenoma incidence |
J:122397
|
|
increased lung tumor incidence |
J:122397
|
|
premature death |
J:122397
|
Krastm1Bbd/Kras+
Mapk3tm1Gpg/Mapk3tm1Gpg
involves: 129/Sv * 129S1/Sv * 129X1/SvJ
|
increased lung non-small cell carcinoma incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Map2k2tm1Chrn/Map2k2tm1Chrn
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
|
increased lung non-small cell carcinoma incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased classified tumor incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
involves: 129S1/Sv * 129X1/SvJ
|
increased lung non-small cell carcinoma incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
involves: 129/Sv * 129S1/Sv * 129X1/SvJ
|
decreased classified tumor incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
involves: 129S1/Sv * 129X1/SvJ
|
increased lung non-small cell carcinoma incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
Map2k2tm1Chrn/Map2k2tm1Chrn
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
|
decreased classified tumor incidence |
J:172200
|
|
premature death |
J:172200
|
Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
increased hemolymphoid system tumor incidence |
J:122397
|
|
increased lung adenoma incidence |
J:122397
|
|
increased lung tumor incidence |
J:122397
|
|
premature death |
J:122397
|
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased cell proliferation |
J:172200
|
Krastm1Mok/Kras+
Nrastm1Mok/Nras+
B6.129S-Nrastm1Mok Krastm1Mok
|
chylous ascites |
J:159024
|
Krastm1Mok/Kras+
Nrastm1Mok/Nras+
involves: 129S/SvEv * C57BL/6 * DBA/2
|
abnormal lymphatic vessel morphology |
J:159024
|
|
chylous ascites |
J:159024
|
Krastm1Mok/Kras+
Nrastm1Mok/Nrastm1Mok
either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * DBA/2)
|
perinatal lethality, incomplete penetrance |
J:135610
|
|
postnatal lethality, complete penetrance |
J:135610
|
Krastm1Mok/Kras+
Nrastm1Mok/Nrastm1Mok
involves: 129S/SvEv * C57BL/6 * DBA/2
|
chylous ascites |
J:159024
|
Krastm1Mok/Kras+
Nrastm1Mok/Nrastm1Mok
Tg(HRAS)2Jic/0
involves: 129S/SvEv * BALB/c * C57BL/6 * DBA/2
|
normal
homeostasis/metabolism phenotype |
J:159024
|
Krastm1Mok/Krastm1Mok
Tg(HRAS)7Mok/0
either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * DBA/2)
|
no abnormal phenotype detected |
J:135610
|
Krastm1Tyj/Kras+
Nrastm1Rak/Nrastm1Rak
involves: 129/Sv * C57BL/6
|
abnormal embryonic hematopoiesis |
J:43433
|
|
abnormal erythropoiesis |
J:43433
|
|
abnormal eye development |
J:43433
|
|
abnormal hepatocyte morphology |
J:43433
|
|
absent visceral yolk sac blood islands |
J:43433
|
|
anemia |
J:43433
|
|
dilated heart |
J:43433
|
|
distended pericardium |
J:43433
|
|
embryonic growth arrest |
J:43433
|
|
embryonic growth retardation |
J:43433
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:43433
|
|
excessive folding of visceral yolk sac |
J:43433
|
|
hydrops fetalis |
J:43433
|
|
increased apoptosis |
J:43433
|
|
increased embryonic tissue cell apoptosis |
J:43433
|
|
pale yolk sac |
J:43433
|
|
pallor |
J:43433
|
|
perinatal lethality, incomplete penetrance |
J:43433
|
|
postnatal lethality, complete penetrance |
J:43433
|
|
short tail |
J:43433
|
Krastm1Tyj/Krastm1Tyj
Nrastm1Rak/Nras+
involves: 129/Sv * C57BL/6
|
embryonic lethality, incomplete penetrance |
J:43433
|
Krastm1Tyj/Krastm1Tyj
Nrastm1Rak/Nrastm1Rak
involves: 129/Sv * C57BL/6
|
embryonic lethality, complete penetrance |
J:43433
|
Krastm2(Kras)Rdl/Krastm2(Kras)Rdl
either: 129 or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
no abnormal phenotype detected |
J:98940
|
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
increased fibrosarcoma incidence |
J:68981
|
|
increased hemangiosarcoma incidence |
J:68981
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
increased fibrosarcoma incidence |
J:68981
|
|
increased hemangiosarcoma incidence |
J:68981
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm2Tyj/Kras+
Trp53tm1Glo/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd
|
abnormal tumor morphology |
J:129627
|
|
increased fibrosarcoma incidence |
J:129627
|
|
increased hemangiosarcoma incidence |
J:129627
|
|
increased lung adenoma incidence |
J:129627
|
|
increased lymphoma incidence |
J:129627
|
|
increased mesothelioma incidence |
J:129627
|
|
increased metastatic potential |
J:129627
|
|
increased papilloma incidence |
J:129627
|
|
increased squamous cell carcinoma incidence |
J:129627
|
|
increased tumor incidence |
J:129627
|
|
premature death |
J:129627
|
Krastm3Tyj/Kras+
Pik3catm1Jdo/Pik3catm1Jdo
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J
|
decreased incidence of induced tumors |
J:122866
|
|
decreased lung tumor incidence |
J:122866
|
Krastm3Tyj/Kras+
Mir21atm1.1Eno/Mir21atm1.1Eno
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
|
decreased lung tumor incidence |
J:164198
|
|
decreased tumor growth/size |
J:164198
|
|
decreased tumor incidence |
J:164198
|
|
increased lung adenoma incidence |
J:164198
|
|
increased T cell derived lymphoma incidence |
J:164198
|
|
lung epithelium hyperplasia |
J:164198
|
|
normal
neoplasm |
J:164198
|
Krastm3Tyj/Kras+
Tg(CAG-Mir21,-EGFP)#Eno/0
involves: 129S4/SvJae * C3H * C57BL/6
|
decreased tumor incidence |
J:164198
|
|
increased lung non-small cell carcinoma incidence |
J:164198
|
|
increased lung tumor incidence |
J:164198
|
|
increased tumor growth/size |
J:164198
|
|
premature death |
J:164198
|
Krastm3Tyj/Krastm3Tyj
Mir301tm1Yoli/Mir301tm1Yoli
involves: 129S4/SvJae * C57BL/6J
|
decreased lung tumor incidence |
J:237900
|
|
decreased lymphoma incidence |
J:237900
|
|
decreased skin tumor incidence |
J:237900
|
|
decreased tumor growth/size |
J:237900
|
|
decreased tumor incidence |
J:237900
|
|
premature death |
J:237900
|
Krastm4.1Tyj/Kras+
Spry2tm1Mrt/Spry2tm1Mrt
involves: 129P2/OlaHsd
|
increased lung tumor incidence |
J:119477
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung adenoma incidence |
J:103407
|
|
increased lung tumor incidence |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
hemoperitoneum |
J:184949
|
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased hamartoma incidence |
J:184949
|
|
increased metastatic potential |
J:184949
|
|
premature death |
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
|
increased carcinoma incidence |
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae
|
decreased incidence of induced tumors |
J:154041
|
|
increased adenocarcinoma incidence |
J:103407
|
|
increased lung adenocarcinoma incidence |
J:103407,
J:154041,
J:195492
|
|
increased lung adenoma incidence |
J:103407,
J:203686
|
|
increased lung tumor incidence |
J:103407
|
|
increased metastatic potential |
J:103407
|
|
premature death |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased metastatic potential |
J:125101
|
|
increased sarcoma incidence |
J:125101,
J:155389
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:124682
|
|
increased metastatic potential |
J:124682
|
|
premature death |
J:124682
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Krt19tm1(cre/ERT)Ggu/Krt19+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac
|
increased carcinoma incidence |
J:172048
|
|
increased gastrointestinal tumor incidence |
J:172048
|
|
increased skin tumor incidence |
J:172048
|
|
lethality, complete penetrance |
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Shhtm2(cre/ERT2)Cjt/Shh+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac
|
normal
integument phenotype |
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
hemoperitoneum |
J:184949
|
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased hamartoma incidence |
J:184949
|
|
increased metastatic potential |
J:184949
|
|
premature death |
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
|
decreased incidence of tumors by chemical induction |
J:124222
|
|
increased squamous cell carcinoma incidence |
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre/ERT)20Efu/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1
|
increased skin squamous cell carcinoma incidence |
J:172048
|
|
skin lesions |
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae
|
abnormal tumor morphology |
J:154041
|
|
decreased incidence of induced tumors |
J:154041
|
|
decreased tumor growth/size |
J:154041
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased adenocarcinoma incidence |
J:103407
|
|
increased lung tumor incidence |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased pancreatic ductal adenocarcinoma incidence |
J:197054
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
|
increased carcinoma incidence |
J:124222
|
|
increased incidence of tumors by chemical induction |
J:124222
|
|
increased spindle cell carcinoma incidence |
J:124222
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased metastatic potential |
J:184935
|
|
increased prostate gland adenocarcinoma incidence |
J:184935
|
|
premature death |
J:184935
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * BALB/c * C57BL/6
|
increased pancreas tumor incidence |
J:164210
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:164210
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:164210
|
|
pancreatic acinar-to-ductal metaplasia |
J:164210
|
|
premature death |
J:164210
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * FVB/N
|
increased skin papilloma incidence |
J:174242
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Gfap-cre)77.6Mvs/0
involves: 129S4/SvJae * BALB/c * C57BL/6NHsd
|
increased classified tumor incidence |
J:154673
|
|
increased neurofibroma incidence |
J:154673
|
|
increased neurofibrosarcoma incidence |
J:154673
|
|
premature death |
J:154673
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae
|
increased ovary tumor incidence |
J:161953
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6J
|
increased endometrial carcinoma incidence |
J:96296
|
|
increased metastatic potential |
J:96296
|
|
premature death |
J:96296
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
increased lung adenocarcinoma incidence |
J:131721
|
|
increased lung adenoma incidence |
J:131721
|
|
increased lung carcinoma incidence |
J:131721
|
|
increased lung tumor incidence |
J:131721
|
|
lung inflammation |
J:131721
|
|
premature death |
J:131721
|
|
tachypnea |
J:131721
|
|
weight loss |
J:131721
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal prostate gland morphology |
J:184935
|
|
increased metastatic potential |
J:184935
|
|
increased prostate gland adenocarcinoma incidence |
J:184935
|
|
premature death |
J:184935
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA
|
abnormal exocrine pancreas morphology |
J:164210
|
|
edema |
J:164210
|
|
exocrine pancreas atrophy |
J:164210
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:164210
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:164210
|
|
pancreatic acinar-to-ductal metaplasia |
J:164210
|
|
postnatal lethality, complete penetrance |
J:164210
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Scgb1a1-cre)1Tauc/0
involves: 129S4/SvJae * C57BL/6
|
abnormal bronchiole morphology |
J:136369
|
|
abnormal bronchus morphology |
J:136369
|
Krastm4Tyj/Kras+
Pik3r2tm1Lca/Pik3r2tm1Lca
involves: 129S4/SvJae * 129S6/SvEvTac
|
increased lung tumor incidence |
J:142254
|
Krastm4Tyj/Kras+
Ptentm2Mak/Pten+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased hepatocellular carcinoma incidence |
J:254370
|
|
increased liver tumor incidence |
J:254370
|
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
bile duct hyperplasia |
J:254370
|
|
distended abdomen |
J:254370
|
|
enlarged liver |
J:254370
|
|
hemorrhagic ascites |
J:254370
|
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased liver tumor incidence |
J:254370
|
|
jaundice |
J:254370
|
|
postnatal growth retardation |
J:254370
|
|
premature death |
J:254370
|
|
weight loss |
J:254370
|
Krastm4Tyj/Kras+
Mapk8tm1Wag/Mapk8+
Mapk9tm1Mka/Mapk9tm1Mka
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased lung tumor incidence |
J:170904
|
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2+
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
increased metastatic potential |
J:116129
|
|
increased pancreas tumor incidence |
J:116129
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116129
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:116129
|
|
premature death |
J:116129
|
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
B6.129-Krastm4Tyj Tgfbr2tm1.2Hlm
|
abnormal myeloid leukocyte morphology |
J:177379
|
|
increased B cell number |
J:177379
|
|
increased lung adenocarcinoma incidence |
J:177379
|
|
increased metastatic potential |
J:177379
|
|
increased T cell number |
J:177379
|
|
premature death |
J:177379
|
Krastm4Tyj/Kras+
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal duodenum morphology |
J:116129
|
|
abnormal hepatic portal vein morphology |
J:116129
|
|
abnormal hepatic portal vein thrombosis |
J:116129
|
|
dilated gallbladder |
J:116129
|
|
distended abdomen |
J:116129
|
|
enlarged spleen |
J:116129
|
|
hemorrhagic ascites |
J:116129
|
|
hepatic necrosis |
J:116129
|
|
increased metastatic potential |
J:116129
|
|
increased pancreas tumor incidence |
J:116129
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116129
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:116129
|
|
jaundice |
J:116129
|
|
paralysis |
J:116129
|
|
premature death |
J:116129
|
|
weight loss |
J:116129
|
Krastm4Tyj/Kras+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Krt1-15-cre/PGR*)22Cot/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J
|
increased adenoma incidence |
J:203922
|
|
increased metastatic potential |
J:203922
|
|
increased papilloma incidence |
J:203922
|
|
increased skin squamous cell carcinoma incidence |
J:203922
|
|
increased skin tumor incidence |
J:203922
|
|
increased trichoepithelioma incidence |
J:203922
|
Krastm4Tyj/Kras+
Stk11tm1.1Rdp/Stk11tm1.1Rdp
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:124682
|
|
increased lung large cell carcinoma incidence |
J:124682
|
|
increased lung squamous cell carcinoma incidence |
J:124682
|
|
increased lung tumor incidence |
J:124682
|
|
increased metastatic potential |
J:124682
|
|
premature death |
J:124682
|
Krastm4Tyj/Kras+
Stk11tm1.1Rdp/Stk11tm1.2Rdp
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:124682
|
|
increased lung large cell carcinoma incidence |
J:124682
|
|
increased lung squamous cell carcinoma incidence |
J:124682
|
|
increased lung tumor incidence |
J:124682
|
|
increased metastatic potential |
J:124682
|
|
premature death |
J:124682
|
Krastm4Tyj/Kras+
Stk11tm1.2Rdp/Stk11tm1.2Rdp
involves: 129S4/SvJae * 129S6/SvEvTac
|
increased macrophage cell number |
J:197037
|
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(MUC1)79.24Gend/0
B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend
|
decreased metastatic potential |
J:138959
|
|
increased pancreas tumor incidence |
J:138959,
J:234412
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:138959
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:138959,
J:234412
|
Krastm4Tyj/Kras+
Rb1tm3Tyj/Rb1tm3Tyj
involves: 129S4/SvJae
|
abnormal bronchiole morphology |
J:147590
|
|
abnormal tumor morphology |
J:147590
|
|
increased lung adenocarcinoma incidence |
J:147590
|
|
increased lung tumor incidence |
J:147590
|
|
premature death |
J:147590
|
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae
|
abnormal pancreas morphology |
J:197054
|
|
normal
neoplasm |
J:197054
|
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S4/SvJae
|
increased lung non-small cell carcinoma incidence |
J:197054
|
|
normal
neoplasm |
J:197054
|
Krastm4Tyj/Kras+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp
|
decreased circulating thyroid-stimulating hormone level |
J:147732
|
|
enlarged thyroid gland |
J:147732
|
|
increased metastatic potential |
J:147732
|
|
increased thyroid carcinoma incidence |
J:147732
|
|
increased thyroxine level |
J:147732
|
|
premature death |
J:147732
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Gev/Trp53tm1Gev
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:220300
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:276349
|
|
premature death |
J:276349
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Y
involves: 129S4/SvJae * FVB/N
|
increased oral papilloma incidence |
J:186717
|
|
increased pancreas tumor incidence |
J:186717
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:186717
|
|
increased skin papilloma incidence |
J:186717
|
|
premature death |
J:186717
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Usp9xtm1Tuv/Usp9x+
involves: 129S4/SvJae * FVB/N
|
increased oral papilloma incidence |
J:186717
|
|
increased pancreas tumor incidence |
J:186717
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:186717
|
|
increased skin papilloma incidence |
J:186717
|
|
premature death |
J:186717
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae
|
hunched posture |
J:191425
|
|
increased lung adenocarcinoma incidence |
J:191425
|
|
increased lung non-small cell carcinoma incidence |
J:191425
|
|
increased lung tumor incidence |
J:103407,
J:191425
|
|
lung inflammation |
J:191425
|
|
respiratory distress |
J:191425
|
|
weight loss |
J:191425
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
cachexia |
J:98936
|
|
cholestasis |
J:98936
|
|
chromosomal instability |
J:98936
|
|
distended abdomen |
J:98936
|
|
hemorrhagic ascites |
J:98936
|
|
increased esophageal papilloma incidence |
J:98936
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:98936
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:98936
|
|
increased papilloma incidence |
J:98936
|
|
increased T cell derived lymphoma incidence |
J:98936
|
|
increased teratocarcinoma incidence |
J:98936
|
|
intestinal obstruction |
J:98936
|
|
premature death |
J:98936
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Zdhhc20em1Jdo/Zdhhc20em1Jdo
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased metastatic potential |
J:348743
|
|
normal
mortality/aging |
J:348743
|
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:103407
|
Krastm4Tyj/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased pancreatic ductal adenocarcinoma incidence |
J:197054
|
Krastm4Tyj/Kras+
Spry2tm1.1Mrt/Spry2tm1.1Mrt
Meox2tm1(cre)Sor/Meox2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N
|
impaired branching involved in bronchus morphogenesis |
J:119477
|
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * FVB/N
|
decreased tumor latency |
J:177853
|
Krastm4Tyj/Kras+
Pik3r1tm1Lca/Pik3r1+
Pik3r2tm1Lca/Pik3r2tm1Lca
involves: 129S4/SvJae * 129S6/SvEvTac
|
increased lung tumor incidence |
J:142254
|
Krastm4Tyj/Kras+
Pik3r1tm1Lca/Pik3r1tm1Lca
Pik3r2tm1Lca/Pik3r2tm1Lca
involves: 129S4/SvJae * 129S6/SvEvTac
|
decreased lung tumor incidence |
J:142254
|
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129 * FVB/N
|
decreased tumor-free survival time |
J:116130
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:116130
|
|
increased tumor incidence |
J:116130
|
|
pancreas cyst |
J:116130
|
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N
|
decreased tumor-free survival time |
J:116130
|
|
increased stomach tumor incidence |
J:116130
|
|
increased tumor incidence |
J:116130
|
|
pancreas cyst |
J:116130
|
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
Ube2ftm1c(EUCOMM)Hmgu/Ube2ftm1c(EUCOMM)Hmgu
involves: 129S4/SvJae * C57BL/6J * C57BL/6N
|
decreased susceptibility to induced pancreatitis |
J:348744
|
|
decreased tumor incidence |
J:348744
|
|
increased body weight |
J:348744
|
|
small pancreas |
J:348744
|
Krastm4Tyj/Kras+
Rbl2tm2Tyj/Rbl2tm2Tyj
involves: 129S4/SvJae
|
abnormal bronchiole morphology |
J:147590
|
|
abnormal tumor morphology |
J:147590
|
|
increased lung adenocarcinoma incidence |
J:147590
|
|
increased lung tumor incidence |
J:147590
|
|
increased tumor growth/size |
J:147590
|
|
premature death |
J:147590
|
|
thick pulmonary interalveolar septum |
J:147590
|
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1b+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal definitive hematopoiesis |
J:122107
|
|
abnormal liver morphology |
J:122107
|
|
abnormal spleen morphology |
J:122107
|
|
decreased lymphocyte cell number |
J:122107
|
|
increased lung adenocarcinoma incidence |
J:122107
|
|
increased lung adenoma incidence |
J:122107
|
|
increased lung tumor incidence |
J:122107
|
|
increased lung weight |
J:122107
|
|
increased neutrophil cell number |
J:122107
|
|
postnatal lethality, incomplete penetrance |
J:122107
|
|
respiratory distress |
J:122107
|
|
weight loss |
J:122107
|
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
increased lung adenoma incidence |
J:122107
|
|
increased lung tumor incidence |
J:122107
|
|
increased lung weight |
J:122107
|
|
postnatal growth retardation |
J:122107
|
|
postnatal lethality, incomplete penetrance |
J:122107
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Flt3-cre)#Ccb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
anemia |
J:247853
|
|
decreased B cell number |
J:247853
|
|
decreased double-negative T cell number |
J:247853
|
|
decreased double-positive T cell number |
J:247853
|
|
decreased hematopoietic stem cell number |
J:247853
|
|
decreased T cell number |
J:247853
|
|
hepatosplenomegaly |
J:247853
|
|
increased dendritic cell number |
J:247853
|
|
increased leukemia incidence |
J:247853
|
|
increased leukocyte cell number |
J:247853
|
|
increased monocyte cell number |
J:247853
|
|
premature death |
J:247853
|
|
thrombocytopenia |
J:247853
|
|
thymus atrophy |
J:247853
|
|
weight loss |
J:247853
|
Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * C57BL/6 * FVB * ICR
|
abnormal centrosome morphology |
J:124222
|
|
abnormal tumor morphology |
J:124222
|
|
increased carcinoma incidence |
J:124222
|
|
increased incidence of tumors by chemical induction |
J:124222
|
|
increased metastatic potential |
J:124222
|
Krastm4Tyj/Kras+
Tg(MUC1)79.24Gend/0
involves: 129S4/SvJae * C57BL/6
|
decreased interferon-gamma secretion |
J:154046
|
|
increased IgG level |
J:154046
|
|
increased IgM level |
J:154046
|
|
increased regulatory T cell number |
J:154046
|
|
uterus adenomyosis |
J:154046
|
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac
|
abnormal colon morphology |
J:254370
|
|
abnormal cystic duct morphology |
J:254370
|
|
abnormal extrahepatic bile duct morphology |
J:254370
|
|
abnormal gallbladder morphology |
J:254370
|
|
abnormal liver morphology |
J:254370
|
|
bronchial epithelial hyperplasia |
J:254370
|
|
dilated gallbladder |
J:254370
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:254370
|
|
lung inflammation |
J:254370
|
|
premature death |
J:254370
|
|
respiratory failure |
J:254370
|
|
stomach mucosa hyperplasia |
J:254370
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm3(CAG-luc)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:141383
|
Krastm4Tyj/Kras+
Tg(Cdh5-cre/ERT2)1Rha/0
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6NCrl * FVB
|
normal
cardiovascular system phenotype |
J:312482
|
|
postnatal lethality |
J:312482
|
Krastm4Tyj/Kras+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
Trp53tm5Tyj/Trp53+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
abnormal bronchoalveolar duct junction morphology |
J:182218
|
|
decreased tumor-free survival time |
J:182218
|
|
increased adenocarcinoma incidence |
J:182218
|
|
increased lung adenoma incidence |
J:182218
|
Krastm4Tyj/Kras+
Rnf7Gt(XE423)Byg/Rnf7+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:207982
|
|
increased lung adenoma incidence |
J:207982
|
|
premature death |
J:207982
|
Krastm4Tyj/Kras+
Rnf7Gt(XE423)Byg/Rnf7tm1.1Ysun
involves: 129P2/OlaHsd * 129S4/SvJae
|
decreased lung tumor incidence |
J:207982
|
|
premature death |
J:207982
|
Krastm4Tyj/Kras+
Pax7tm2.1(cre/ERT2)Fan/Pax7+
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
increased sarcoma incidence |
J:205518
|
|
increased tumor incidence |
J:205518
|
Krastm4Tyj/Kras+
Tg(CAG-Bgeo,-tsA58T)T26Ichi/0
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
hemorrhagic ascites |
J:214846
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:214846
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:214846
|
|
pancreatic acinar-to-ductal metaplasia |
J:214846
|
|
postnatal lethality, complete penetrance |
J:214846
|
Krastm4Tyj/Kras+
Lrrc17tm1Nik/Lrrc17+
Srpk2tm1Nik/Srpk2+
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA
|
abnormal blood cell morphology/development |
J:161558
|
|
anemia |
J:161558
|
|
increased leukocyte cell number |
J:161558
|
|
premature death |
J:161558
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
B6.Cg-Krastm4Tyj Map2k7tm1.1Twad/Map2k7tm1.2Twad
|
abnormal DNA repair |
J:170904
|
|
increased lung adenocarcinoma incidence |
J:170904
|
|
increased lung tumor incidence |
J:170904
|
|
premature death |
J:170904
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Tg(Trp53)bSrn/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA
|
normal
neoplasm |
J:170904
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6
|
increased lung adenocarcinoma incidence |
J:170904
|
|
increased lung tumor incidence |
J:170904
|
Krastm4Tyj/Kras+
Trp53tm4Att/Trp53tm4Att
involves: 129S4/SvJae
|
increased organ/body region tumor incidence |
J:173395
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scrib+
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:216266
|
|
lung epithelium hyperplasia |
J:216266
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scrib+
Tg(Pbsn-cre)20Fwan/0
involves: 129S4/SvJae * FVB/NCrl
|
abnormal intestine morphology |
J:178461
|
|
abnormal prostate gland physiology |
J:178461
|
|
increased prostate gland adenocarcinoma incidence |
J:178461
|
|
increased prostate intraepithelial neoplasia incidence |
J:178461
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scribtm1.1Phum
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:216266
|
Krastm4Tyj/Kras+
Scribtm1.1Phum/Scribtm1.1Phum
Tg(Pbsn-cre)20Fwan/0
involves: 129S4/SvJae * FVB/NCrl
|
abnormal intestine morphology |
J:178461
|
|
abnormal prostate gland physiology |
J:178461
|
|
increased carcinoma incidence |
J:178461
|
|
increased prostate gland adenocarcinoma incidence |
J:178461
|
|
increased prostate intraepithelial neoplasia incidence |
J:178461
|
|
premature death |
J:178461
|
|
prostate gland hyperplasia |
J:178461
|
Krastm4Tyj/Kras+
Sftpctm1(cre/ERT2)Blh/Sftpc+
Trp53tm5Tyj/Trp53+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
abnormal pulmonary alveolus morphology |
J:182218
|
|
increased adenocarcinoma incidence |
J:182218
|
|
increased lung adenoma incidence |
J:182218
|
|
premature death |
J:182218
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Pdx1-cre)6Tuv/0
TgTn(sb-T2/Onc)#Dla/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
|
increased pancreas tumor incidence |
J:186717
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:186717
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:186717
|
|
premature death |
J:186717
|
Krastm4Tyj/Kras+
Stk11tm1.1Gne/Stk11tm1.1Gne
involves: 129S4/SvJae * C57BL/6N
|
pancreas cyst |
J:195229
|
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
decreased tumor-free survival time |
J:195738
|
|
increased lung adenocarcinoma incidence |
J:195738
|
|
increased lung adenoma incidence |
J:195738
|
|
increased type II pneumocyte number |
J:195738
|
Krastm4Tyj/Kras+
Ralatm1.2Cjm/Ralatm1.2Cjm
Ralbtm1.1Cjm/Ralbtm1.2Cjm
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
decreased tumor growth/size |
J:199742
|
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
involves: 129S4/SvJae * C57BL/6
|
increased lung adenoma incidence |
J:203686
|
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased lung adenoma incidence |
J:203686
|
Krastm4Tyj/Kras+
Myod1tm1.1(cre/ERT,TVA)Gcg/Myod1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased sarcoma incidence |
J:205518
|
|
increased tumor incidence |
J:205518
|
Krastm4Tyj/Kras+
Plcl1tm1.1Matk/Plcl1tm1.1Matk
involves: 129S4/SvJae * C57BL/6
|
increased tumor incidence |
J:207384
|
Krastm4Tyj/Kras+
Trp53tm1Lejo/Trp53tm1Lejo
involves: 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:187012
|
|
increased lung non-small cell carcinoma incidence |
J:187012
|
Krastm4Tyj/Kras+
Siva1tm1.1Att/Siva1tm1.2Att
involves: 129S4/SvJae * C57BL/6
|
abnormal lung adenoma incidence |
J:223572
|
|
abnormal lung epithelium morphology |
J:223572
|
|
decreased lung tumor incidence |
J:223572
|
Krastm4Tyj/Kras+
Siva1tm1.2Att/Siva1+
involves: 129S4/SvJae * C57BL/6
|
abnormal lung adenoma incidence |
J:223572
|
|
abnormal lung epithelium morphology |
J:223572
|
|
decreased lung tumor incidence |
J:223572
|
Krastm4Tyj/Kras+
Tg(CAG-HPV16E6E7,-luc)#Mspi/0
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N * FVB/NJ
|
increased oral papilloma incidence |
J:210533
|
Krastm4Tyj/Kras+
Rab11fip1tm1.1Jicn/Rab11fip1tm1.1Jicn
Tg(Pdx1-cre)6Tuv/0
Trp53tm2.1Tyj/Trp53+
involves: 129S4/SvJae * FVB/N
|
decreased metastatic potential |
J:244261
|
|
normal
mortality/aging |
J:244261
|
|
normal
neoplasm |
J:244261
|
Krastm4Tyj/Kras+
Tg(Erbb2*)#Maed/0
Ptf1atm1.1(cre)Cvw/Ptf1a+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J
|
abnormal pancreatic acinar cell morphology |
J:262746
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:262746
|
Krastm4Tyj/Kras+
Ube2cem1Gpt/Ube2cem1Gpt
involves: 129S4/SvJae * C57BL/6J
|
decreased lung tumor incidence |
J:333347
|
|
increased tumor-free survival time |
J:333347
|
Krastm4Tyj/Kras+
Ube2sem1Ysun/Ube2sem1Ysun
involves: 129S4/SvJae
|
decreased tumor-free survival time |
J:333347
|
|
increased lung tumor incidence |
J:333347
|
Krastm4Tyj/Krastm4Tyj
Mir182tm1.1Dgk/Mir182+
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased metastatic potential |
J:217635
|
Krastm4Tyj/Krastm4Tyj
Mir182tm1.1Dgk/Mir182tm1.1Dgk
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased metastatic potential |
J:217635
|
Krastm4Tyj/Krastm4Tyj
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Tg(Six3-cre)69Frty/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal cone electrophysiology |
J:174095
|
|
abnormal rod electrophysiology |
J:174095
|
|
decreased a-wave amplitude |
J:174095
|
|
decreased b-wave amplitude |
J:174095
|
|
normal
vision/eye phenotype |
J:174095
|
Krastm4Tyj/Krastm4Tyj
Trim33tm1Los/Trim33tm1Los
Tg(Pdx1-cre)89.1Dam/0
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal pancreas morphology |
J:151781
|
|
dilated pancreatic duct |
J:151781
|
|
disorganized pancreatic islets |
J:151781
|
|
increased pancreas tumor incidence |
J:151781
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:151781
|
|
pancreas cyst |
J:151781
|
|
pancreas hyperplasia |
J:151781
|
|
pancreas inflammation |
J:151781
|
Krastm4Tyj/Krastm4Tyj
Ugdhtm1.1Xzh/Ugdhtm1.1Xzh
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA/J
|
abnormal lacrimal gland development |
J:185652
|
|
absent lacrimal glands |
J:185652
|
Krastm4Tyj/Krastm4Tyj
Yap1tm1.1Dupa/Yap1tm1.1Dupa
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
increased hepatocellular carcinoma incidence |
J:162628
|
Krastm5Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased sarcoma incidence |
J:172206
|
Krastm5Tyj/Kras+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6
|
increased lung adenocarcinoma incidence |
J:180576
|
|
increased sarcoma incidence |
J:180576
|
|
increased tumor growth/size |
J:180576
|
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53+
involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6
|
increased pancreatic ductal adenocarcinoma incidence |
J:248550
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:248550
|
|
premature death |
J:248550
|
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6
|
increased pancreatic ductal adenocarcinoma incidence |
J:248550
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:248550
|
|
premature death |
J:248550
|
Pggt1btm1Mbrg/Pggt1btm1Mbrg
Krastm4Tyj/Kras+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal cell morphology |
J:122107
|
|
decreased cell proliferation |
J:122107
|
Slc25a11em1Syki/Slc25a11+
Krastm3Tyj/Kras+
involves: 129S * C57BL/6
|
decreased lung tumor incidence |
J:294965
|
Analysis Tools
Excel File